Neuroprotective efficacy and therapeutic window of the high-affinity N- methyl-D-aspartate antagonist conantokin-G: In vitro (primary cerebellar neurons) and in vivo (rat model of transient focal brain ischemia) studies

Journal of Pharmacology and Experimental Therapeutics

Volumn 294, Issue 1, 2000, Pages 378-386

  Williams, Anthony J ^a   Dave, Jitendra R ^a   Phillips, James B ^a   Lin, Yu ^a   Mccabe, R Tyler ^b   Tortella, Frank C ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Cognetix Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONANTOKIN G; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; VERATRIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; CEREBELLUM; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ELECTROENCEPHALOGRAPHY; EMBRYO; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SOMNOLENCE;

ANIMALS; BLOOD PRESSURE; CALCIUM; CELLS, CULTURED; CONOTOXINS; ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; ISCHEMIC ATTACK, TRANSIENT; MALE; N-METHYLASPARTATE; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033933764     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Andrews B, Weinstein P and Faden A (1988) Computerized cortical surface electroencephalography after temporal middle cerebral artery occlusion in rabbits. Neurosurgery 22:681-686.
2. Barinaga M (1998) Stroke-damaged neurons may commit cellular suicide. Science (Wash DC) 281:1302-1303.
3. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL and Bartkowski HM (1986) Evaluation of 2,3,5-triphenyl tetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17:472-476.
4. Blandl T, Prorok M and Castellino F (1998) NMDA-receptor antagonist requirements in conantokin-G. FEBS Lett 435:257-262.
5. Chen Z, Blandl T, Prorok M, Warder S, Li Leping, Zhu Y, Pedersen L, Ni F and Castellino F (1998) Conformational changes in conantokin-G induced upon binding of calcium and magnesium as revealed by NMR structural analysis. J Biol Chem 273:16248-16258.
6. Cheung N, Pascoe C, Giardina S, John C and Beart P (1998) Micromolar L-glutamate induces extensive apoptosis in a apoptotic-necrotic continuum of insult-dependent, excitotoxic injury in cultured cortical neurons. Neuropharmacology 37:1419-1429.
7. Clemens JA and Panetta JA (1994) Neuroprotection by antioxidants in models of global and focal ischemia. Ann NY Acad Sci 738:250-256.
8. De Keyser J, Sulter G and Luiten PG (1999) Clinical trials with neuroprotective drugs in acute ischaemic strokes: Are we doing the right thing? Trends Neurosci 22:535-540.
9. Donevan SR and McCabe RT (2000) Conantokin G is an NR2B selective antagonist of NMDA receptors. Mol Pharmacol, in press.
10. Dyker A and Lees K (1998) Duration of neuroprotective treatment for ischemic stroke. Stroke 29:535-542.
11. Eguchi Y, Shimizu S and Tsujimoto Y (1997) Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 57:1835-1840.
12. Garcia J, Yoshida Y, Chen H, Li Y, Zhang Z, Lian J, Chen S and Chopp M (1993) Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. Am J Physiol 142:623-635.
13. Gill R, Sibson N, Hatfield R, Burdett N, Carpenter T, Hall L and Pickard J (1995) A comparison of the early development of ischemic damage following permanent middle cerebral artery occlusion in rats as assessed using magnetic resonance imaging and histology. J Cereb Blood Flow Metab 15:1-11.
14. Kaufmann A, Firlik A, Fukui M, Weschler L, Jungries C and Yonas H (1999) Ischemic core and penumbra in ischemic stroke. Stroke 30:93-99.
15. Kawasaki-Yatsugi S, Ichiki C, Yatsugi S, Sasamata SS and Yamaguchi T (1998) YM90K, an AMPA receptor antagonist, protects against ischemic damage caused by permanent and transient middle cerebral artery occlusion in rats. Naunyn-Schmiedeberg's Arch Pharmacol 368:586-591.
16. Klette K, Lin Y, Clapp L, DeCoster M, Moreton J and Tortella F (1997) Neuroprotective sigma ligands attenuate NMDA and trans-ACPD-induced calcium signaling in rat primary neurons. Brain Res 756:231-240.
17. Koroshetz W and Moskowitz M (1996) Emerging treatments for stroke in humans. Trends Pharmacol Sci 17:227-233.
18. Margaill I, Parmentier S, Callebert J, Allix M, Boulu R and Plotkine M (1996) Short therapeutic window for MK801 in transient focal cerebral ischemia in normotensive rats. J Cereb Blood Flow Metab 16:107-113.
19. Martin L, Al-Abdulla N, Brambrink A, Kirsch J, Sieber F and Portera-Cailliau C (1998) Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: A perspective on the contributions of apoptosis and necrosis. Brain Res Bull 46:281-309.
20. Muir K and Grosset D (1999) Neuroprotection for acute stroke: Making clinical trials work. Stroke 30:180-182.
21. Muir KW and Lees KR (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503-513.
22. Nicotera P and Lipton S (1999) Excitotoxins in neuronal apoptosis and necrosis. J Cereb Blood Flow Metab 19:583-591.
23. Pantoni L, Sarti C and Domenico I (1998) Cytokines and cell adhesion molecules in cerebral ischemia. Arterioscler Thromb Vasc Biol 18:503-513.
24. Park CK, Mendelow AD, Graham DI, McCulloch J and Teasdale GM (1988) Correlation of triphenyl tetrazolium chloride perfusion staining with conventional neurohistology in the detection of early brain ischemia. Neuropathol Appl Neurobiol 14:289-298.
25. Phillips J, Williams A, Elliot P, Adams J and Tortella F (2000) The proteasome inhibitor, PS519, reduces infarction in a rat model of cerebral ischemia. Stroke, in press.
26. Phillips JB, Williams AJ, Elliott PJ and Tortella FC (1999) A novel proteasome inhibitor, PS519, shows neuroprotective efficacy in a rat model of transient focal ischemia. FASEB Abstr 13:A1099.
27. Prorok M and Castellino F (1998) Thermodynamics of binding of calcium, magnesium, and zinc to the N-methyl-D-aspartate receptor ion channel peptidic inhibitors, conantokin-G and conantokin-T. J Biol Chem 273:19573-19578.
28. Ringelstein E, Biniek R, Weiller C, Ammeling B, Nolte P and Thron A (1992) Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 42:289-298.
29. Schwamm L, Koroshetz W, Sorensen A, Wang B, Copen W, Budzik R, Rordorf G, Buonanno F, Schaefer P and Gonzalez R (1998) Time course of lesion development patients with acute stroke: Serial diffusion-weighted and hemodynamic-weighted magnetic resonance imaging. Stroke 29:2268-2276.
30. Skolnick P, Boje K, Miller R, Pennington M and Maccecchini M (1992) Noncompetitive inhibition of N-methyl-D-aspartate by conantokin-G: Evidence for an allosteric interaction at polyamine sites. J Neurochem 59:1516-1521.
31. Slusher BS, Vornov JJ, Thomas AG, Hum PD, Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu X-CM, Tortella FC, Wozniak KM, Yudoff M, Potter BM and Jackson PF (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 5:1396-1402.
32. Steinberg G, Panahian N, Perez-Pinzon M, Sun G, Modi M and Sepinwall J (1995) Narrow temporal therapeutic window for NMDA antagonist protection against focal cerebral ischemia Neurobiol Dis 2:109-118.
33. Tallarida RJ and Murray RB (1987) Manual of Pharmacologic Calculations with Computer Programs. Springer-Verlag, New York.
34. Tatlisumak T, Takano K, Carano R, Miller L, Foster A and Fisher M (1998) Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke 29:1952-1958.
35. Tortella F, Britton P, Williams A, Lu X and Newman A (1999) Neuroprotection (focal ischemia) and neurotoxicity (electroencephalographic) studies in rats with AHN649, a 3-amino analog of dextromethorphan and low-affinity N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther 291:399-408.
36. Tortella F, Rose J, Robles L, Moreton J, Hughes J and Hunter J (1997) EEG spectral analysis of the neuroprotective kappa opioids enadoline and PD117302. J Pharmacol Exp Ther 282:286-293.
37. Whetsell WO (1996) Current concepts of excitotoxicity. J Neuropathol Exp Neurol 55:113.
38. Williams A, Long J, Phillips JB, Dave JR, Lin Y, Cui P, McCabe T, Nielsen J, Layer R, Zhou L and Tortella FC (1998) Conantokin-G decreases hypoxic/hypoglycemic (H/H) injury in cultured rat neurons and decreases infarction in a rat model of focal cerebral ischemia. Neurosci Abstr 24:978.
39. Zhou L, Szendrei G, Fossom L, Maccecchini M, Skolnick P and Otvos L (1996) Synthetic analogues of conantokin-G: NMDA antagonists acting through a novel polyamine-coupled site. J Neurochem 66:620-628.